Regeneron REGN

HealthcareMarket cap $100B3 connections

Regeneron makes Eylea (leading treatment for wet AMD and diabetic macular edema - billions of eyes depend on it), Dupixent (blockbuster for eczema, asthma, and nasal polyps with $13B+ sales), and Kevzara. Its Praluent (cholesterol) and Libtayo (cancer) round out a deep pipeline. Dupixent may be one of the most versatile drugs ever developed - currently in 60+ clinical trials for new indications.

Explore Regeneron on the interactive map Relationship timeline Find a path to another company

Partners 2

Strategic partnerships, joint products and alliances

AmgenHealthcare · $160BCompeting biologic drug makers
SanofiHealthcare · $130BDupixent co-development

Competitors 1

Companies it competes with

Vertex PharmaHealthcare · $120BRare disease drug competition

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Regeneron's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=REGN" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Regeneron on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.